Prospects for the pharmacological treatment of human prion diseases

CNS Drugs

Volumn 10, Issue 2, 1998, Pages 83-89

  Adjou, Karim Tarik ^a   Deslys, Jean Philippe ^a   Demaimay, Rémi ^a   Seman, Michel ^b   Dormont, Dominique ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; AMPHOTERICIN B; AMPHOTERICIN B DERIVATIVE; ANTHRACYCLINE; ANTIMONIOTUNGSTATE; CONGO RED; DEXTRAN SULFATE; MS 8209; PENTOSAN POLYSULFATE; POLYANION; PRION PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CREUTZFELDT JAKOB DISEASE; HUMAN; PRION DISEASE; PRIORITY JOURNAL;

EID: 0031850779     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810020-00001     Document Type: Article

References (38)

1. Bolton DC, McKinley MP, Prusiner SB. Identification of a protein that purities with the scrapie prion. Science 1982; 218: 1309-11
2. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-44
3. Dormont D, Delpech B, Delpech A, et al. Hyperproduction de protéine gliofibrillaire acide (GFAP) au cours de l'évolution de la tremblante expérimentale de la souris. C R Acad Sci 1981; 293: 53-6
4. Mackenzie A. Immunohistochemical demonstration of glial fibrillary acidic protein in scrapie. J Comp Pathol 1983; 93: 251-9
5. Lazarini F, Deslys JP, Dormont D. Variations in prion protein and glial fibrillary acidic protein messenger RNAs in the brain of scrapie-infected newborn mouse. J Gen Virol 1992; 73: 1645-8
6. Will RG, Ironside JW, Zeidler M. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921-5
7. Chazot G, Broussolle E, Lapras C. New variant of Creutzfeldt-Jakob disease in a 26-year-old French man [letter]. Lancet 1996; 347: 1181
8. Lasmczas CI, Deslys JP, Demaimay R, et al. BSE transmission to macaques. Nature 1996; 381: 743-4
9. Collinge J, Sidle KCL, Meads J, et al. Molecular analyses of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-90
10. Bruce ME, Will RG, Ironside JW, et al. Transmission to mice indicate that 'new variant' CJD is caused by the BSF agent. Nature 1997; 389: 498-501
11. Cousens SN, Vynnycky E, Zeidler M, et al. Predicting the CJD epidemic in humans. Nature 1997; 385: 197-8
12. Brown P. A therapeutic panorama of the spongiform encephalopathies. Antiviral Chem Chemother 1990; 1: 75-83
13. Adjou KT, Deslys JP, Demaimay R, et al. Prohing the dynamics of prion diseases with amphotericin B. Trends Microbiol 1997; 5: 27-31
14. Kimberlin RH, Walker CA. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 1983; 78: 9-18
15. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in spleen. J Gen Virol 1984; 65: 1325-30
16. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice hy hetero-polvanion 23, dextran sulfate, and some other polyanions. Antimicrob Agents Chemother 1986; 30: 409-13
17. Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991; 72: 457-60
18. Ladogana A, Casaccia P, Ingrosso L, et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992; 73: 661-5
19. Caughey B, Ernest D, Race R. Congo red inhibition of scrapie agent replication. J Virol 1993; 67: 643-50
20. Ingrosso L, Ladogana LA, Pocchiari M. Congo red prolongs the incubation period in scrapie-infected hamsters. J Virol 1995; 69: 506-8
21. Barbieri B, Guiliani FC, Bordoni T, et al. Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Res 1987; 47: 4001-6
22. Tagliavini F, McArthur RA, Canciani B, et al. Effectiveness of anthracycline against experimental prion disease in Syrian hamsters. Science 1997; 276: 1119-22
23. Amyx H, Salazar AM, Gajdusek DC, et al. Chemotherapeutic trials in experimental slow virus disease [abstract]. Neurology 1984; 34: 149
24. Pocchiari M, Schmittinger S, Ladogana A, et al. Effects of amphotericin B in intracerebrally scrapie inoculated hamster. In: Court L, Dormont D, Brown P, et al. editors. Unconventional virus diseases of the central nervous system. Paris: CEA Diffusion, 1989: 314-23
25. Saint Julien L, Joly V, Seman M, et al. Activity of MS-8209, a nonester amphotericin B derivative, in treatment of experimental systemic mycoses. Antimicrob Agents Chemother 1992; 36: 2722-8
26. Cefai D, Hadida F, Jung M, et al. MS-8209, a new amphotericin B derivative that inhibits HIV-1 replication in vitro and restores T-cell activation via the CD3/TcR in HIV-infected CD4+ cells. AIDS 1991; 5: 1453-8
27. Pleskoff O, Seman M, Alizon M. Amphotericin B derivative blocks human immunodeficiency virus type 1 entry after CD4 binding: effect on virus cell fusion hut not on cell-cell fusion. J Virol 1995; 69: 570-4
28. Pleskoff O, Sol N, Marrakchi H, et al. Possible role of the V3 domain of gp 120 in resistance to amphotericin B derivative (MS-8209) blocking human immunodeficiency virus entry. J Virol 1996; 70: 8247-51
29. Magierowska-Jung M, Cefaï D, Marrakchi H, et al. In vitro determination of antiviral activity of MS-8209, a new amphotericin B derivative, against primary isolates of HIV-1. Res Virol 1996; 147: 313-8
30. Demaimay R, Adjou KT, Lasmézas CI, et al. Pharmacological studies of a new derivative of amphotericin-B, MS-8209, in mouse and hamster scrapie. J Gen Virol 1994; 75: 2499-503
31. Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of antiscrapie drugs. J Infect Dis 1989; 160: 795-802
32. Adjou KT, Demaimay R, Lasméas CI, et al. MS-8209, a new amphotericin B derivative, provides enhanced efficacy in delaying hamster scrapie. Antimicrob Agents Chemother 1995; 39: 2810-2
33. Adjou KT, Demaimay R, Lasmézas CI, et al. Differential effects of a new amphotericin B derivative, MS-8209, on mouse BSE and scrapie: implications for the mechanism of action of polyene antibiotics. Res Virol 1996; 147: 213-8
34. Xi YG, Ingrosso L, Ladogana A, et al. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 1992; 356: 598-601
35. McKenzie D, Kaczkowski J, Marsh R, et al. Amphotericin B delays both scrapie agent replication and PrP-res accumulation early in infection. J Virol 1994; 68: 7534-6
36. Müller WEG, Ushijima H, Schröder HC, et al. Cytoprotective effect of NMDA receptor antagonists on prion protein (PrionSc)-induced toxicity in rat cortical cell cultures. Eur J Pharmacol 1993; 246: 261-7
37. Masullo C, Macchi G, Xi YG, et al. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 1992; 165: 784-5
38. Hsich G, Kinney K, Gibbs CJ, et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongi-form encephalopathies. N Engl J Med 1996; 335: 924-30